Compounds > methamphetamine

methamphetamine and lobelane

methamphetamine has been researched along with lobelane in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Crooks, PA; Deaciuc, AG; Ding, D; Dwoskin, LP; Nickell, JR; Penthala, NR1
Crooks, PA; Ding, D; Dwoskin, LP; Nickell, JR1
Crooks, PA; Deaciuc, G; Dwoskin, LP; Krishnamurthy, S; Nickell, JR; Norrholm, S; Siripurapu, KB; Zheng, G1
Crooks, PA; Dwoskin, LP; Gabriela Deaciuc, A; Vartak, AP1
Crooks, PA; Dwoskin, LP; Nickell, JR; Siripurapu, KB; Vartak, A1

Reviews

1 review(s) available for methamphetamine and lobelane

ArticleYear
The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.
    Advances in pharmacology (San Diego, Calif.), 2014, Volume: 69

    Topics: Amphetamine-Related Disorders; Animals; Drug Delivery Systems; Drug Discovery; Humans; Lobeline; Methamphetamine; Protein Binding; Treatment Outcome; Vesicular Monoamine Transport Proteins

2014

Other Studies

4 other study(ies) available for methamphetamine and lobelane

ArticleYear
Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake.
    Bioorganic & medicinal chemistry, 2013, Nov-01, Volume: 21, Issue:21

    Topics: Animals; Azetidines; Dopamine; Dopamine Uptake Inhibitors; Isomerism; Kinetics; Lobeline; Protein Binding; Rats; Synaptic Vesicles; Tritium; Vesicular Monoamine Transport Proteins

2013
Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
    Bioorganic & medicinal chemistry letters, 2015, Jul-01, Volume: 25, Issue:13

    Topics: Amphetamine-Related Disorders; Animals; Binding Sites; Dopamine; Humans; In Vitro Techniques; Kinetics; Lobeline; Methamphetamine; Rats; Structure-Activity Relationship; Synaptic Vesicles; Tetrabenazine; Vesicular Monoamine Transport Proteins

2015
Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 332, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine-Related Disorders; Animals; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Evaluation, Preclinical; Lobeline; Male; Methamphetamine; Nicotinic Agonists; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Synaptic Vesicles; Synaptosomes; Vesicular Monoamine Transport Proteins

2010
Quinlobelane: a water-soluble lobelane analogue and inhibitor of VMAT2.
    Bioorganic & medicinal chemistry letters, 2010, Jun-15, Volume: 20, Issue:12

    Topics: Animals; Binding Sites; Dopamine; Humans; Hydrogenation; Hydroquinones; Lobelia; Lobeline; Methamphetamine; Solubility; Structure-Activity Relationship; Substance-Related Disorders; Synaptic Vesicles; Vesicular Monoamine Transport Proteins

2010